Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

Sun Yat-sen University

Status: Active, not recruiting

Conditions: TYRX Absorbable Antibacterial Envelope; CIED Infection

Treatments: Device: TYRX Absorbable Antibacterial Envelope

Study type: Observational

Funder types: Other

Identifiers

NCT06710873

SYSKY-2024-911-01

Details and patient eligibility

About

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Full description

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who received the TYRX absorbable antimicrobial envelopes at our hospital from December 2023 to September 2024

Exclusion criteria

• Allergies to the envelope materials or antimicrobial drugs (minocycline and other tetracyclines, rifampin)
• Existing infections at the CIED implantation site
• Pregnant or breastfeeding women
• children and adolescents